Compare Novavax Inc (NVAX) vs Open Text Corporation (OTEX) Price & Performance

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Open Text Corporation (OTEX) trades at $23.27, down 5.87% over the past day, with a bullish technical signal despite recent weakness. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.23 versus $1.02 expected, and maintains solid fundamentals including a 73.74% gross margin and 12.26% net income margin. Recent news highlights cloud revenue growth and a $105 million AI investment in Europe.

Outlook remains positive with a consensus price target of $29.33 implying 26% upside, supported by earnings beats and strategic AI investments. Risks include high debt levels and competitive pressures in the software sector. The stock offers value with a P/E of 9.29 and a 4.7% dividend yield.